Box III Text of the abstract

Methods for targeting cancer cells for depletion, wherein CD47 blocking agent is combined with one or more immuno-modulating agents, such as agonist of immune costimulatory molecule (e.g. anti-CD40 and anti-OX40 antibodies) and antagonist of immune inhibitory molecule (e.g. anti-CTLA4, anti-PD1/PDL1, anti-TIM3 and anti-LAG3 antibodies). Such combination therapy produces enhanced cell depletion when compared to monotherapy.